Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2024

 

Commission File Number 001- 41291

 

Meihua International Medical Technologies Co., Ltd. 

(Translation of registrant’s name into English)

 

88 Tongda Road, Touqiao Town

Guangling District, Yangzhou, 225000

People’s Republic of China

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒      Form 40-F ☐

 

 

 

 

 

 

As previously disclosed, on April 2, 2024, Meihua International Medical Technologies Co., Ltd. (the “Company”) received written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, the Company was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market.

 

Since then, Nasdaq has determined that for the last 21 consecutive business days, from September 4, 2024 to October 2, 2024, the closing bid price of the Company’s ordinary shares has been at $1.00 per share or greater. On October 3, 2024, the Staff notified the Company that it has regained compliance with Listing Rule 5450(a)(1), and the matter is now closed.

 

On October 7, 2024, the Company issued a press release entitled “Meihua International Medical Technologies Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement.” A copy of the press release is furnished herewith as Exhibit 99.1.

 

Exhibit Index

 

Exhibit No.		Description
99.1		Press Release, dated October 7, 2024, entitled Meihua International Medical Technologies Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement.”

 

1

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.  

 

	Meihua International Medical Technologies Co., Ltd.
Dated: October 7, 2024
	By:	/s/ Xin Wang
	Name:	Xin Wang
	Title:	Chief Executive Officer (Principal Executive Officer)

 

 

2

 

 

Exhibit 99.1

 

Meihua International Medical Technologies Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement

 

YANGZHOU, China, October 7, 2024 -- Meihua International Medical Technologies Co., Ltd. (“MHUA” or the “Company”) (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries in China, today announced that on October 3, 2024, it received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”).

 

As previously reported, the Company was notified on April 2, 2024, that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Nasdaq Minimum Bid Price Requirement.

 

Since then, Nasdaq has determined that for the last 21 consecutive business days, from September 4, 2024 to October 2, 2024, the closing bid price of the Company’s Ordinary Shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5450(a)(1), and the matter is now closed.

 

About Meihua International Medical Technologies Co., Ltd.

 

Meihua International Medical Technologies Co., Ltd. is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under the Company’s own brands and are also sourced and distributed from other manufacturers. The Company has received an international “CE” certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 1,000 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania.

 

For more information, please visit www.meihuamed.com.

 

Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua.

 

For investor and media inquiries, please contact:

 

IR Department

Email: [e-mail]

Tel: [phone]

 

Christensen

Yang Song

Email: [e-mail]

Tel: [phone]

---